This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes
by Kinjel Shah
The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Pharma ETFs Soar on Robust Q2 Earnings
by Sweta Killa
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress
by Zacks Equity Research
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.
Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.
BioNTech (BNTX) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio
by Benjamin Rains
Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...
5 Growth ETFs & Stocks to Ride the Market Rally
by Sweta Killa
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus
by Kinjel Shah
Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.
Coronavirus Vaccine Efforts Key to Moderna (MRNA) Q2 Earnings
by Zacks Equity Research
Moderna (MRNA) is progressing with coronavirus vaccine development. The company has initiated a late-stage study and investors will likely focus any preliminary data from the study
Glaxo (GSK) Q2 Earnings & Sales Miss Estimates, Decline Y/Y
by Zacks Equity Research
Glaxo (GSK) witnesses disruption from COVID-19 pandemic in Vaccines and reversal of stockpiling benefits from the first quarter in Pharmaceuticals and Consumer Healthcare, which hurt sales.
Stock Market News for Jul 29, 2020
by Zacks Equity Research
Benchmarks slipped into the negative territory on Tuesday as investors kept a close watch on a second coronavirus relief package in consideration by lawmakers, along with mixed second-quarter corporate earnings report.
Buy Caterpillar Stock Ahead of Q2 Earnings, Stay for the Dividend?
by Benjamin Rains
Caterpillar is set to release its second quarter fiscal 2020 financial results before the opening bell on Friday, July 31. Is it time to buy CAT stock?
3 Cheap Gold & Silver Stocks to Buy Right Now as Haven Prices Surge
by Benjamin Rains
It might be time for investors to take advantage of rising gold and silver prices. Let's dive into three such stocks trading under $20 per share that could be enticing...
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Pfizer (PFE) Q2 Earnings Top, Sales Hurt by Coronavirus, View Up
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings while missing the same for sales. It slightly raises its financial outlook for the year.
All Eyes on "The Swamp;" Plus Q2 Reports from PFE, MCD & More
by Mark Vickery
Senate Republicans on Capitol Hill have unveiled their long-awaited stimulus package to replace the CARES Act, which expires at the end of this week. Also, the Fed begins a two-day session.
HEALS Act & Earnings Data Deluge
by Zacks Equity Research
HEALS Act & Earnings Data Deluge
The Zacks Analyst Blog Highlights: Facebook, Verizon Communications, Pfizer, Novartis and Philip Morris International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Verizon Communications, Pfizer, Novartis and Philip Morris International
Coronavirus Vaccine Development Puts These Stocks in Focus
by Ritujay Ghosh
Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.
Pfizer (PFE) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 21.88% and -0.63%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?